A method for estimating hepatitis B virus incidence rates in volunteer blood donors. National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Study

Transfusion
J J KorelitzG B Schreiber

Abstract

Calculations of the incidence of hepatitis B virus (HBV) infections in the blood donor setting that are based solely on data for seroconversion to hepatitis B surface antigen (HBsAg) will underestimate the incidence due to the transient nature of antigenemia. Estimates based on antibody to hepatitis B core antigen will overestimate the incidence due to false-positive results caused by the nonspecificity of the test. Serologic test results were obtained from multiple-time volunteer donors at five United States blood centers from January 1991 through December 1993. The observed HBsAg seroconversion rate was multiplied by an adjustment factor, derived from the weighted average probability of a positive HBsAg test for HBV-infected donors who become chronic carriers, for donors with a primary antibody response without detectable antigenemia, and for donors who develop transient antigenemia. Among 586,507 multiple-time donors giving 2,318,356 donations and observed for 822,426 person-years, the HBsAg incidence rate was 4.01 per 100,000 person-years. On the basis of prior reports of the duration of HBsAg positivity and the observed distribution of interdonation intervals among the study group, there was an estimated 53-percent chance ...Continue Reading

Associated Clinical Trials

Citations

Oct 5, 2010·Transactions of the Royal Society of Tropical Medicine and Hygiene·Secil OzkanIsil Maral
Jan 13, 2001·Journal of Viral Hepatitis·E J Kupek
Nov 4, 1998·Transfusion Medicine·E L MurphyG N Vyas
Jan 1, 1996·Vox Sanguinis·J P AuBuchon
Jun 22, 2002·Transfusion·George B SchreiberUNKNOWN Retrovirus Epidemiology Donor Study
Mar 30, 2000·Transfusion·C F Högman, F Knutson
Sep 12, 2001·Transfusion·S H Kleinman, M P Busch
Oct 19, 2002·Transfusion·Manuel AlvarezJ M Hernández
Oct 19, 2002·Transfusion·Josiane PillonelUNKNOWN Transfusion-Transmissible Agents Working Group of the French Society of Blood Transfusion
Oct 19, 2002·Transfusion·Simone A GlynnUNKNOWN NHLBI Retrovirus Epidemiology Donor Study
Nov 9, 2002·Transfusion·Clive R SeedUNKNOWN Virology Subcommittee of the National Donor and Product Safety Committee, Australian Red Cross Blood Service
Aug 20, 2004·The New England Journal of Medicine·Shimian ZouUNKNOWN Tissue Safety Study Group
Sep 29, 2011·Transfusion Medicine Reviews·Sheila F O'BrienSteven H Kleinman
Nov 21, 2009·Transfusion clinique et biologique : journal de la Société française de transfusion sanguine·A O Touré-FallL Diakhaté
Aug 5, 2008·Transfusion·Syria LapercheUNKNOWN Transfusion-Transmissible Agents Working Group, French National Society of Blood Transfusion
Jun 8, 2006·Vox Sanguinis·L Comanor, P Holland
Nov 18, 2006·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·G ZahariadisJ K Preiksaitis
May 4, 2004·Transfusion clinique et biologique : journal de la Société française de transfusion sanguine·J PillonelUNKNOWN Centre de transfusion sanguine des armées
Jul 13, 2006·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·Steven H Kleinman, Michael P Busch
Apr 1, 2006·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·Robério P A Almeida, Divina D D P Cardoso

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.